KMB's 54-Year Dividend Streak Under Pressure as Kenvue Deal Strains Cash Flow

What happened

Kimberly-Clark's five-decade dividend growth streak is now openly questioned as its $48.7 billion Kenvue acquisition and razor-thin free cash flow coverage collide. Operating free cash flow payout hit 118.5% and EPS payout 101.3% in the first nine months of 2025, leaving no buffer before Kenvue integration costs and higher interest expense arrive. Tariffs, value-tier pricing, and transformation spending compressed Q3 2025 adjusted gross margin by 170 basis points to 36.8%, even as volumes grew. Management has reaffirmed its commitment to the dividend but has not set explicit deleveraging targets, relying instead on Suzano JV proceeds and working-capital normalization. With the stock at $97.92 trading near 16.5x earnings, we see limited risk-adjusted upside and maintain our POTENTIAL SELL rating.

Implication

Investors reliant on KMB's dividend should stress-test their income assumptions, as the payout is now funded by balance sheet and asset sales rather than sustainable operating cash flow. The next 12 months offer few positive catalysts: Kenvue synergies won't materialize until after the deal closes in 2H26, while tariffs, litigation, and integration costs will continue to pressure margins and cash. A rally toward $115 would be an opportunity to reduce exposure, as that level already embeds an optimistic synergy and litigation outcome; our bear case implies $80. We would only become constructive if management outlines a concrete deleveraging roadmap and operating free cash flow payout returns below 90% on a sustained basis. Until then, KMB is a show-me story with downside skew.

Thesis delta

Our prior thesis already flagged the dividend coverage stress and rated KMB POTENTIAL SELL; this news article does not change the rating but amplifies the visibility of the risk. The explicit spotlight on the 54-year streak may accelerate investor repricing, particularly among income funds, and increases the probability of a dividend reset if coverage doesn't improve by 2027. We maintain conviction 4.0, with trim above $115 and attractive entry only at $90 or below if deleveraging and synergy execution become credible.